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Introduction
T
wo different types of drugs can be used in 
the treatment of chronic hepatitis B (CHB): 
interferon  alpha  and  nucleos(t)ide  analogues 
(NUCs). NUCs for hepatitis B virus (HBV) therapy 
belong to three subclasses: L-nucleosides (lamivudine 
[LAM],  telbivudine  [LdT],  and  emtricitabine), 
deoxyguanosine  analogues  (entecavir  [ETV])  and 
acyclic  nucleoside  phosphonates  (adefovir  [ADV] 
and tenofovir [TDF]). LAM, LdT, ETV, ADV, and 
TDF  have  been  approved  in  Europe,  the  United 
States, and most Asian and Latin American countries, 
for HBV treatment (1-3).
A  major  concern  with  NUC  treatment  is  the 
selection  of  antiviral  –  resistant  mutations.  Long 
term therapy with NUCs, in particular, is associated 
with an increasing risk of the development of drug 
resistance (4, 5). Mutations selected under NUCs can 
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Hepatitis B virus (HBV) strains, resistant to at least two anti-HBV agents from different subclasses of nucleos(t)ide analogues 
(NUCs) without a cross-resistance profile, are defined as multidrug-resistant. However, there are limited in vivo data for   
resistance to multiple NUCs. In this study, we report the case of the emergence of a multidrug-resistant HBV strain in a 
Turkish patient receiving sequential therapy. Polymerase gene mutations of HBV were detected using direct sequencing, 
line probe assay and clonal analysis. Twelve months after the start of lamivudine (LAM) therapy, virological breakthrough 
occurred (4.2E+07 IU/ml) and the rtM204V variant was detected in the patient’s sera: adefovir (ADV) was added to the 
therapy. ADV therapy was continued as monotherapy for 11 months, until the occurrence of clinical breakthrough i.e. alanine 
aminotransferase (ALT) 60 IU/L, and emergence of drug resistance to ADV (rtN236T). At that time, switch therapy was resumed 
with ADV + entecavir (ETV) in combination for 5 months. In the 18th month of the ETV monotherapy, direct sequencing showed 
reduced susceptibility to ETV (rtL180M+rtM204V). Currently, ETV + tenofovir (TDF) are being used as antiviral treatment 
and the HBV DNA load has decreased substantially (<1.0E+02 IU/ml). In conclusion, we have detected an HBV strain with 
multidrug-resistance, which had a very fast course of development. Patients with a multidrug-resistant profile should be 
more frequently followed up both by direct sequencing and line probe assay, for the detection of possible novel HBV variants 
and low level mutants present in the viral population, in case of the sudden emergence of drug resistance. 
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be split into two groups: those that cause resistance 
that sometimes leads to decreased viral fitness, and 
compensatory  mutations,  which  partially  or  fully 
restore the level of viral fitness (6, 7).
HBV strains resistant to at least two anti-HBV 
agents from different subclasses of NUCs without 
a cross-resistance profile are defined as multidrug-
resistant  (3).  The  multidrug-resistant  strains  are 
more likely to develop in sequential therapy (8, 9). 
The emergence of a multidrug-resistant HBV strain 
under sequential oral anti-HBV therapy has recently 
been documented for the first time (10). Nevertheless, 
there are limited in vivo data for resistance to multiple 
NUCs (3).
Turkey, with about 6500 individuals newly infected 
with HBV a year, is numbered among those regions 
with intermediate endemicity (11-13). Moreover, a few 
studies of Turkish patients with treated or untreated 
CHB infections have frequently indicated HBV drug 
resistance  as  rtM204V  (YVDD  variant),  rtM204I 
(YIDD  variant)  and,  rarely,  as  rtM204S  (YSDD 
variant)  mutations  with  or  without  compensatory 
mutations, such as rtV173L and rtL180M  (14-17). 
Although little is known about multidrug-resistant 
HBV  strains,  a  recently  reported  novel  mutation 
pattern emerging during LAM treatment shows cross 
- resistance to ADV treatment (9).
In this study, we report the case of a Turkish patient 
who had clinical and genotypical breakthrough under 
NUC treatment, and who was shown to be multidrug-
resistant to sequential therapy.
Case Report
The  patient  was  a  33-year-old 
female  with  hepatitis  B  e  antigen 
(HBeAg)-negative  CHB.  A  liver 
biopsy in 2004 revealed CHB and 
the  patient  was  scored  as  grade 
II and stage II. Liver damage was 
determined according to Knodell’s 
classification  (18).  Oral  antiviral 
therapy  was  started  with  LAM 
(Zeffix100-  mg/day,  Glaxo 
Wellcome Laboratories, Middlesex, 
UK). However, 12 months after the 
start  of  LAM  therapy,  virological 
breakthrough  occurred  (HBV 
DNA  4.2E+07  IU/ml)  and  the 
YVDD  variant  was  detected.  ADV  (Hepsera-
10  mg/day,  Gilead  Sciences,  Inc.  Foster  City, 
CA 94404. U.S.A) was added to LAM therapy in 
the  13th  month  of  antiviral  treatment.  After  two 
months, ALT normalization and a decrease in the 
HBV viral load were observed. ADV therapy was 
continued  as  monotherapy  for  11  months.  After 
the occurrence of clinical breakthrough i.e. alanine 
aminotransferase (ALT) 60 IU/L, and the emergence 
of drug resistance to ADV, switch therapy was agreed 
on, and antiviral treatment was resumed with ADV + 
ETV (Baraclude1 - mg/day, Bristol-Myers Squibb 
Company Princeton, NJ U.S.A) in combination for 
5 months, followed by ETV monotherapy for 18 
months. In the 18th month of ETV monotherapy, 
ALT was at a normal level, and the HBV viral load 
dropped  to  3.54E+03  IU/ml.  Direct  sequencing, 
however, showed reduced susceptibilty (intermediate) 
to ETV. After the occurrence of resistance to ETV, 
TDF  was  added  on  to  the  ETV  monotherapy  as 
the  current  treatment  regimen,  and  ETV  + TDF 
(Viread -245 mg/day, Gilead Sciences, Inc. Foster 
City, CA U.S.A) therapy decreased the HBV DNA 
load (2.84E+02 IU/ml). Currently,the latest HBV 
DNA levels of the patient over the last 6 months 
are  <100  IU/ml.  Sequential  NUC  therapies  and 
developing  primer  /  compensatory  resistance 
detected  by  direct  sequencing,  line  probe  assays 
(LIPA) and clonal analysis of the HBV variants (in 2 
different sera samples – taken at the 11th month of 
ADV therapy and at the 4th month of ETV + TDF 
therapy) are summarized in Table 1. HBV DNA load 
status and ALT levels with primer drug resistance are 
plotted in Fig 1.
Hepatitis serology and HBV DNA assays
Hepatitis B surface antigens (HBsAg), anti-HBsAg 
Figure  1.  Obtained  sequential  data  on  the  HBV-DNA  loads  and 
ALT levels with primer drug resistance during sequential nucleos(t)ide 
analogues therapy.Hepatitis Monthly, Spring 2010; 10(2): 141-146
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antibodies (anti-HBs), anti-HBeAg antibodies (anti-
HBeAg) and anti-hepatitis C virus antibodies (anti-
HCV) were determined by the microparticle enzyme-
immunoassay method and anti-D virus antibodies 
(anti-HDV)  by  an  enzyme-immunoassay  (Abbott 
Laboratories, IL,USA). HBV DNA levels were tested 
using  a  commercial  real-  time  polymerase  chain 
reaction (real time PCR) (Iontek Biotechnology Inc, 
İstanbul, Turkey). A nested polymerase chain reaction 
(PCR) for HBV was used, as previously reported by 
Karatayli et al. (9).
The sequencing of the HBV polymerase gene region
Briefly, a pair of primers was designed (forward: 5’-
TCGTGGTGGACTTCTCTCAATT-3’  and  reverse: 
5’-  CGTTGACAGACTTTCCAATCAAT-3’)  for 
amplification of the HBV polymerase region. The 
PCR conditions were: 95ºC for 15 min, and then 45 
cycles consisting of 95ºC for 45 s, 56ºC for 45 s, and 
72ºC for 45 s. The final concentration of the primers 
was 0.3 μM. The size of the HBV amplicon was 
742-bp. All PCR products were purified using the 
High Pure PCR Product Purification Kit® (Roche 
Diagnostics  GmbH,  Mannheim,  Germany)  and 
directly sequenced with ABI PRISM 310 Genetic 
Analyzer®  equipment,  using  the  DYEnamic  ET 
Terminator  Cycle  Sequencing  Kit®  (Amersham 
Pharmacia Biotech Inc, Piscataway, NJ USA). For 
the cycle sequencing, the following thermal protocol 
was used: 35 cycles consisting of 95ºC for 20 s, 50ºC 
for 25 s, and finally 60ºC for 2 min. The reverse 
primer was used as the sequencing primer at a final 
concentration  of  0.5  uM.  The  electropherogram-
obtained  sequences  were  assembled  using  Vector 
NTI® v5.1 (InforMaxTM InvitrogenTM life science 
software, Frederick, MD 21704, USA).
Determination of HBV genotypes
HBV  genotypes  were  determined  by  means 
of the genotyping tool of the National Center for 
Biotechnology  Information  (NCBI,  U.S  National 
Library of Medicine, Bethesda, MD USA, http://
www.ncbi.nih.gov/projects/genotyping/formpage.
cgi.), which identifies the genotype, based on viral 
nucleotide sequences. The genotyping tool works by 
using BLAST to compare a query sequence to a set of 
reference sequences for known genotypes (19).
Determination of polymerase gene mutations 
Polymerase gene mutations of HBV were detected 
by manual analysis, a drug resistance tool and LIPA. 
The  Genafor/Arevir  -  geno2pheno  drug  resistance 
tool  (Center  of  Advanced  European  Studies  and 
Research,  Bonn,Germany,  http://coreceptor.bioinf.
Table 1. Genotypic resistance patterns of multidrug-resistant HBV strain in sequential NUCs mono and 
combine therapy.
Sequential NUCs therapy
(Dec. 2004 – Feb. 2009)
Resistance detection 
method (application time 
in the treatment)
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a LAM – associated amino acids at position M552, L528 and V555 is previous nomenclature (20). b ETV intermediate: by L180M+M204V mutations; according to EASL 
Clinical Practice Guidelines 2009 (1). c NT: Not tested. d TDF intermediate: by N236T mutation; according to EASL Clinical Practice Guidelines 2009 (1). e Detected 
after nested HBV PCR. f When band densities in LIPA assays are compared, wild-type probe band is denser than variant-type probe bands in this LIPA assay and of equal 
density in others LIPA assays.Hepatitis Monthly, Spring 2010; 10(1): 141-146
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mpi-inf.mpg.de/)  for  HBV  is  a  database  that  is 
specifically  designed  for  rapid  computer  -  assisted 
virtual  phenotyping  of  HBV,  and  accepts  genome 
(nucleic  acid)  sequences  as  input.  Geno2pheno 
searches for homology between input sequences and 
others already stored in its database, which also stores 
relevant clinical data for drug resistance and surface 
(S) gene mutations. The data accumulated by direct 
sequencing were analyzed either manually or by using 
the geno2pheno tool. The geno2pheno tool searches 
for HBV drug resistance mutations in the rt amino 
acids at positions 80, 169, 173, 180, 181, 184, 194, 
202,  204,  215,  233,  236,  and  250.  However,  the 
reverse transcriptase (rt) domain of the polymerase at 
amino acid positions 84, 85, 214, 237, and 238 was 
additionally searched for, manually (4, 20). The Inno-
LIPA HBV DR v2 assay (Inno-LIPA; Innogenetics 
NV, Ghent, Belgium) was performed according to 
the manufacturer’s instructions using the QuantiTect 
SYBR  Green  PCR  kit  (Qiagen,  Hilden,Germany). 
The assay is based on the amplification of a part of 
the viral polymerase gene by the provided primers and 
reverse hybridization by probes coated on a strip. It 
detects HBV polymerase wild-type and known drug-
induced mutations associated with LAM and ADV 
resistance (codons 80, 173, 180/181, 204, and 236).
The patient was infected with genotype D of HBV 
and the data, obtained from positions 80 through 
250 of the amino acids of the HBV polymerase gene 
by direct sequencing, were analyzed either manually 
or by using the geno2pheno tool. The results were 
similar in both cases. 
Clonal Analysis of HBV variants
Clonal analysis has been performed on 2 different 
sera  samples  obtained  and  also  on  3  different 
extraction  samples  obtained  during  the  patient’s 
therapy.  However,  the  cloning  procedure  was 
successful in only 2 sera samples, and clones obtained 
from these sera samples have been sequenced.
For the cloning of the HBV polymerase region, 
a  700  bp  PCR  amplification  covering  the  whole 
HBV pol gene was done, using the following primers; 
CLC188  5’-TCCCCAACCTCCAATCAC-3’  and 
CLC887 5’-AAACCCAAAAGACCCACAA-3’. The 
PCR was run for 35 cycles, with denaturation at 95 °C 
for 45 s, annealing at 55 °C for 30 s, and elongation 
at 72 °C for 1 min. The amplified 700 bp HBV 
polymerase region was cloned into a TA vector by 
using the TOPO-XL-PCR Cloning kit (Invitrogen 
Corp. Carlsbad, CA USA) and the constructs were 
then sequenced using the Big Dye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA, USA) in an ABI Prism 3130 XL Genetic 
Analyser  (Perkin  Elmer,  Foster  City,  CA,  USA) 
according to the manufacturer’s instructions.
Discussion
Towards the end of 2003, a case report of a patient 
with HBV infection and antiviral resistance to ADV, 
after failure of initial therapy with LAM, heralded the 
new era of HBV multidrug-resistance (21). Actually, the 
emergence of HBV variants should have been expected 
due to the characteristics of the HBV genome. The 
major causes of drug resistance include viral factors. 
such as the kinetics of viral production and clearance; 
lack  of  a  proofreading  mechanism  during  reverse 
transcription, which creates a large HBV quasispecies 
pool; and the replication fitness of the viral quasispecies 
(22). The emergence of multidrug-resistant strains does 
not seem to be a common phenomenon (23). There 
have been several studies testing HBV mutants for a 
multidrug-resistance profile to different antiviral drugs 
(10, 24). A new mutation pattern, rt181S + rtM204I, 
which arose under LAM treatment, conferring cross-
resistance  to  ADV  treatment,  has  recently  been 
reported in a Turkish patient (9). Thus, the presence 
of  multidrug-resistant  HBV  strains  is  still  a  major 
therapeutic problem.
This study has demonstrated that the occurrence 
of an HBV strain with multidrug-resistant variants, 
is  associated  with  primer  LAM  and  primer  ADV 
resistance, and with reduced susceptibility to ETV 
and TDF, according to the new EASL Clinical Practice 
Guidelines (1). Three primer drug resistance mutations 
in different domains of HBV viral polymerase, the 
rtA181V/T,  rtL180M+  rtM204V  mutations  and 
the  rtN236T  mutation,  were  characterized  in  the 
same genome, which might explain the multidrug-
resistance profile. The resistance to LAM and ADV 
of  an  engineered  laboratory  mutant  HBV  strain 
harbouring  the  rtL180M  +  rtM204V+  rtN236T 
mutations pattern has been described in vitro, and 
it was suggested that non-optimal strategies based 
on the sequential use of NUCs might result in the 
emergence  of  selected  multidrug-resistant  strains 
(25). In our patient, we applied the “add-on” strategy 
between sequential monotherapies. The most effective 
treatment of multidrug resistance is its prevention, by 
avoiding the sequential use of NUCs monotherapies. 
However, the choice of the initial treatment strategy 
may affect the efficacy of future treatment options 
(23, 26). Moreover, for the avoidance of the emergence 
of  multidrug-resistance,  immune  control  of  HBV 
would probably be required, in addition to oral anti-
HBV agents in treating chronic hepatitis infection 
(3).  On  the  other  hand,  drug  resistance  to  LAM 
developed after 12 months of initial therapy, and to Hepatitis Monthly, Spring 2010; 10(2): 141-146
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ADV after 13 months of LAM + ADV combination 
therapy  in  our  case.  Those  were  resistances  that 
developed very suddenly.The cumulative incidence 
of HBV resistance to LAM and ADV in published 
pivotal trials in NUC-naive patients in year 1 was 
24% and 0%, respectively (1).
The rtM204V mutation in our case was detected as 
a primer drug resistance to LAM in all applied direct 
sequencing assays and reconfirmed by LIPA findings. 
But, the rtN236T mutation responsible for primer 
ADV drug resistance (besides rtA181V/T) found by 
LIPAwas never detected in direct sequencing. However, 
clonal analysis of the HBV variants revealed that the 
rtM204V + rtV173L + rtL180M mutations pattern 
was present in all clones in the sera sample of the 4th 
month of ETV + TDF therapy (Table 2). Hence, all 
of the methods applied in this study are sufficient to 
establish that the rtM204V + rtV173L + rtL180M 
mutations are in the same genome and predominate. 
Detected rtM204I and rtA181V mutations in clones 
2, 5 and 4, however, in the other serum sample clonally 
analyzed, was not consistent with the results of direct 
sequencing and LIPA assay (Table 1). This might have 
been due to the low level of these mutations in the 
HBV quasispecies pool, undetectable by sequencing 
and LIPA assay. Interestingly, in addition to known 
primary  and  compensatory  mutations,  some 
previously undocumented mutations, such as R120K, 
H126R, S135Y, and H248N, were detected in 2 of 
the 5 clones of serum samples from the 11th month 
of ADV treatment, and in all clones of serum samples 
from the 4th month of ETV+TDF treatment.
On  the  other  hand,  compensatory  mutations 
such  as  rtV173L,  rtQ215H,  and  rtL80I/V  have 
been detected only by direct sequencing and LIPA, 
respectively.  However,  only  the  rtL180M  mutation 
was detected by both methods. Most of the clones 
from the sera samples taken in the 11th month of ADV 
therapy revealed the presence of the rtL80V mutation 
in  the  clonal  analysis  of  the  HBV  variants. These 
findings suggested that all methods used in this study 
for resistance detection of HBV variants had different 
sensitivities and accordingly, both methods should be 
used on follow-up of the infected case with multidrug- 
resistant strains, for effective treatment management. 
NUC  resistance  in  HBV  variants  is  commonly 
detected by the direct sequencing of HBV DNA (27). 
However,  this  assay  is  time-consuming  for  a  large 
number of clinical samples, but is suitable for large-
region screening, in viral genomes. LIPA technology 
has been developed for more sensitive detection of 
resistance  mutation  in  the  HBV  polymerase  gene. 
This technology is useful for the rapid and accurate 
detection of mutants, which make up as little as 5%-
10%  of  the  HBV  population,  but  it  only  detects 
known mutations for LAM and ADV, together with 
wild type variants (28, 29). In our study, applied LIPA 
assays showed wild types for the N236 and M204 
amino acid positions, and this finding suggests that 
wild-type  virus  strains  of  rtN236T  and  rtM204V 
variants  may  still  be  reproducible  in  this  patient’s 
sera. Also, this possibility may be also specified for 
compensatory  mutations  (L80,V173,  L180/A181). 
In this study, amino acids in positions 80 through 
250 of the HBV polymerase gene have been manually 
analyzed and the results were similar to those from 
the geno2pheno tool analysis. Databases, such as the 
geno2pheno tool are a convenient approach in HBV 
mutation phenotyping. Large regions of sequence data 
can be rapidly interpreted for amino acid substitutions 
with the help of this database.
Some compensatory mutations demonstrated in 
Table 2. Clonal analysis results of multidrug-resistant HBV strain in sera samples.
Clone Sample Mutation
L80V L91I R120K H126R S135Y V173L L180M A181V M204I L231V Y245H H248N
1
Sera, 
11th month in 
ADV 
therapy
CTT¦ATT AGG¦AAG CAC¦CGC TCC¦TAC CAT¦AAT
2 TTA¦GTA CTT¦ATT ATG¦ATT TAC¦CAC
3 TTA¦GTA CTG¦GTG
4 GCT¦GTT
5 TTA¦GTA CTT¦ATT ATG¦ATT TAC¦CAC
6 CTT¦ATT AGG¦AAG CAC¦CGC TCC¦TAC CAT¦AAT







CTT¦ATT AGG¦AAG CAC¦CGC TCC¦TAC GTG¦TTG CTG¦ATG ATG¦GTG CAT¦AAT
2 CTT¦ATT AGG¦AAG CAC¦CGC TCC¦TAC GTG¦TTG CTG¦ATG ATG¦GTG CAT¦AAT
3 CTT¦ATT AGG¦AAG CAC¦CGC TCC¦TAC GTG¦TTG CTG¦ATG ATG¦GTG CAT¦AAT
4 CTT¦ATT AGG¦AAG CAC¦CGC TCC¦TAC GTG¦TTG CTG¦ATG ATG¦GTG CAT¦AAT
5 CTT¦ATT AGG¦AAG CAC¦CGC TCC¦TAC GTG¦TTG CTG¦ATG ATG¦GTG CAT¦AATHepatitis Monthly, Spring 2010; 10(1): 141-146
146 Multidrug-Resistant HBV Strain in a Chronic Turkish Patient
this study (rtL80I/V, rtV173L, rtL180M, rtQ215H) 
help  to  restore  the  replication  efficiency  of  the 
mutant virus, but they tend to occur in the presence 
of antiviral selection pressure (30). The viral load may 
be an indirect marker of the replication of efficiency. 
There was no significant relationship between the 
sequential  HBV  DNA  loads  of  the  patient  with 
the compensatory mutations in the present study. 
Actually,there has also been no significant relationship 
between  primer  drug  resistance  mutations  (the 
YVDD variant and the rtN236T variant), and HBV 
DNA loads and ALT levels. (Fig.1). The replication 
capacity  of  the  detected  multidrug-resistant  strain 
requires further investigation.
In conclusion, we have detected an HBV strain 
with  multidrug-resistance  associated  with  primer 
LAM  and  primer  ADV  resistance  and  reduced 
susceptibility to ETV and TDF. There has not been 
much experience with multidrug-resistance in CHB 
patients. Patients with multidrug-resistance could be 
more frequently followed up by direct sequencing 
and LIPA, for the emergence of drug resistance in 
possible new and/or low level variants of HBV.
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